TMCI — Treace Medical Concepts Income Statement
0.000.00%
- $422.62m
- $400.25m
- $209.36m
- 81
- 32
- 93
- 78
Annual income statement for Treace Medical Concepts, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 57.4 | 94.4 | 142 | 187 | 209 |
Cost of Revenue | |||||
Gross Profit | 44.9 | 77.5 | 116 | 152 | 168 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 56.5 | 111 | 181 | 239 | 265 |
Operating Profit | 0.855 | -16.5 | -39.6 | -51.4 | -55.7 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.67 | -20.6 | -42.8 | -49.5 | -55.7 |
Net Income After Taxes | -3.67 | -20.6 | -42.8 | -49.5 | -55.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.67 | -20.6 | -42.8 | -49.5 | -55.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.31 | -20.7 | -42.8 | -49.5 | -55.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.085 | -0.429 | -0.688 | -0.814 | -0.897 |
Dividends per Share |